InhaleRx Limited (IRX.AX)
AUD 0.02
(0.0%)
AUD 0.02
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.41 Million AUD | 26.49% |
| 2022 | -1.94 Million AUD | -71.08% |
| 2021 | -1.12 Million AUD | -10.07% |
| 2020 | -1.21 Million AUD | 35.34% |
| 2019 | -1.83 Million AUD | 17.15% |
| 2018 | -1.89 Million AUD | -6.73% |
| 2017 | -2.65 Million AUD | -411.6% |
| 2016 | -348.25 Thousand AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 24.67 Thousand AUD | 103.16% |
| 2024 Q2 | -807.24 Thousand AUD | -1967.3% |
| 2023 Q2 | -1.84 Million AUD | -163.15% |
| 2023 Q1 | -701.69 Thousand AUD | 31.41% |
| 2023 FY | - AUD | -36.63% |
| 2023 Q4 | -781.02 Thousand AUD | -14986.34% |
| 2023 Q3 | -5177.00 AUD | 99.72% |
| 2022 FY | - AUD | -71.08% |
| 2022 Q4 | -1.02 Million AUD | -101.81% |
| 2022 Q2 | -930.56 Thousand AUD | -100.0% |
| 2022 Q1 | -465.28 Thousand AUD | 16.06% |
| 2022 Q3 | -506.91 Thousand AUD | 45.53% |
| 2021 FY | - AUD | -10.07% |
| 2021 Q4 | -554.29 Thousand AUD | -100.0% |
| 2021 Q1 | -277.68 Thousand AUD | 62.45% |
| 2021 Q2 | -555.37 Thousand AUD | -100.0% |
| 2021 Q3 | -277.14 Thousand AUD | 50.1% |
| 2020 FY | - AUD | 35.34% |
| 2020 Q4 | -739.42 Thousand AUD | -108.63% |
| 2020 Q1 | -217.78 Thousand AUD | 46.25% |
| 2020 Q2 | -466.15 Thousand AUD | -114.04% |
| 2020 Q3 | -354.42 Thousand AUD | 23.97% |
| 2019 Q2 | -982.29 Thousand AUD | -98.35% |
| 2019 Q1 | -495.23 Thousand AUD | -4.05% |
| 2019 Q3 | -398.69 Thousand AUD | 59.41% |
| 2019 FY | - AUD | 17.15% |
| 2019 Q4 | -405.17 Thousand AUD | -1.63% |
| 2018 Q1 | -466.5 Thousand AUD | 21.96% |
| 2018 FY | - AUD | -6.73% |
| 2018 Q4 | -475.93 Thousand AUD | 0.0% |
| 2018 Q3 | -475.93 Thousand AUD | -2.02% |
| 2018 Q2 | -466.5 Thousand AUD | 0.0% |
| 2017 Q2 | -646.72 Thousand AUD | 0.0% |
| 2017 Q4 | -597.8 Thousand AUD | 0.0% |
| 2017 FY | - AUD | -411.6% |
| 2017 Q1 | -646.72 Thousand AUD | 0.0% |
| 2017 Q3 | -597.8 Thousand AUD | 7.56% |
| 2016 FY | - AUD | 0.0% |
| 2016 Q2 | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| 4DMedical Limited | -36.06 Million AUD | 96.08% |
| Adherium Limited | -11.56 Million AUD | 87.775% |
| Aroa Biosurgery Limited | -7.36 Million AUD | 80.792% |
| Atomo Diagnostics Limited | -5.42 Million AUD | 73.933% |
| Anteris Technologies Ltd | -66.9 Million AUD | 97.887% |
| Control Bionics Limited | -5.15 Million AUD | 72.592% |
| CardieX Limited | -6.71 Million AUD | 78.937% |
| Compumedics Limited | 2.78 Million AUD | 150.69% |
| Cochlear Limited | 579.5 Million AUD | 100.244% |
| CleanSpace Holdings Limited | -3.49 Million AUD | 59.513% |
| Cyclopharm Limited | -3.03 Million AUD | 53.417% |
| EMVision Medical Devices Ltd | -2.09 Million AUD | 32.396% |
| Nova Eye Medical Limited | -5.97 Million AUD | 76.355% |
| HeraMED Limited | -3.97 Million AUD | 64.408% |
| Imricor Medical Systems, Inc. | -21.87 Million AUD | 93.536% |
| ImpediMed Limited | -22.05 Million AUD | 93.589% |
| LBT Innovations Limited | -4.04 Million AUD | 65.084% |
| Micro-X Limited | -14.35 Million AUD | 90.149% |
| Neurotech International Limited | -8.24 Million AUD | 82.851% |
| OncoSil Medical Limited | -11.97 Million AUD | 88.195% |
| PolyNovo Limited | 5.17 Million AUD | 127.345% |
| Respiri Limited | -7.04 Million AUD | 79.947% |
| SomnoMed Limited | -2.32 Million AUD | 39.288% |
| Universal Biosensors, Inc. | -9.09 Million AUD | 84.448% |
| Uscom Limited | -1.5 Million AUD | 6.332% |
| Visioneering Technologies, Inc. | -4.91 Million AUD | 71.25% |